09.00

Welcome and introduction

Frédéric LIOTÉ (France), Hang-Korng EA (France), Alexander SO (Switzerland)

MORNING - SESSION 1

Chairs: Hang-Korng EA (France)

09.05

Introduction to modulation of inflammation keynotes

Hang-Korng EA (France)

09.10

Targeting long non coding RNAs (lncRNAs) in Osteoarthritis

Stephanie FANUCCHI (Netherlands)

09.45

Multi-omic single-cell data integration and regulatory inference in diseases

Yang LI (Germany)

MORNING - SESSION 2

Chairs: Hang-Korng EA (France), Alexander SO (Switzerland)

10.45

Macrophages and atherosclerosis

Guilia CHINETTI (France)

11.10

An endogenous lipid as a trigger for chronic joint pain

Emmanuel DEVAL (France)

11.35

The Crystal Blueprint : Decoding Clonal Hematopoiesis of Indeterminate Potential

Isidoro COBO (USA)

AFTERNOON - SESSION 1

Chairs: Jessica BERTRAND (Germany), Tania CRISAN (Romania)

13.30

Pathogenic role of CPP crystals

Augustin LATOURTE (France)

13.55

Chondrocalcinosis and Osteoarthritis

Cindy BOER (Netherlands)

Oral communications - session 1

14.20

Genome-wide Association Study Reveals ENPP1 as a Candidate Therapeutic Target in Chondrocalcinosis

Riku TAKEI (USA)

14.30

Identification of calcification types of meniscus samples and correlation with degradation severity in osteoarthritis patients

Hilke LEMKE (Germany)

14.40

Differential DNA methylation patterns in hyperuricemic and normouricemic individuals

Medeea BADII (Romania)

14.50

PBMC cytokine response to crystal-related stimuli: how much variation can we explain?

Nicholas SUMPTER (Netherlands)

AFTERNOON - SESSION 2

Chairs: Jessica BERTRAND (Germany), Hervé KEMPF (France)

15.15

Arterial calcification heterogeneity

Thibaut QUILLARD (France)

15.35

Bone formation and arterial medial calcification: how similar are they?

Isabel ORRISS (United Kingdom)

Oral communications - session 2

Chairs: Nathalie BUSSO (Switzerland), Sonia NASI (Switzerland / Netherlands)

16.00

Raman spectroscopic characterization of calcium pyrophosphate crystals in synovial fluid identifies presence of triclinic CPP only

Tom NIESSINK (Netherlands)

16.10

Association of Chondrocalcinosis with disease activity and drug response in Rheumatoid Arthritis: Baseline characteristics of the Swiss Rheumatoid Arthritis Outcomes cohort

Tobias MANIGOLD (Switzerland)

16.20

Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic calcification

Sonia NASI (Switzerland / Netherlands)

16.30

Positive allosteric modulators (PAMs) of cystathionine gamma lyase (CSE) increase hydrogen sulfide (H2S) and inhibit NLRP3 activation

Alexander SO (Switzerland)

16.40

Intracellular fate of monosodium urate and calcium pyrophosphate crystals in macrophages and their dissolution

Charles LEROY (France)

16.50

Characterization of the zone of calcified cartilage and the chondrocyte phenotype in osteoarthritis patients

Andrea SCHWAB (Netherlands - Germany)

17.00

Hyperuricemia and inflammation in chronic inflammatory arthritis: A post-hoc analysis of the CARMA project

Antonio AVILÉS HERNÁNDEZ (Spain)

17.15

Novel imaging techniques to detect and characterize calcium crystal deposition

Fabio BECCE (Switzerland)

08.45

Welcome & introduction

Alexander SO (Switzerland), Hang-Korng EA (France)

MORNING - SESSION 1

Chairs: Tania CRISAN (Romania), Alexander SO (Switzerland)

09.00

Discovery of Common Variants and Novel Genes Associated with Urate Levels: Insights from the CKDGen Round 5 GWAS Project

Sahar GHASEMI (Germany)

09.30

Genetics of gout in Pacific (Live video)

Tristan PASCART (France)

10.00

What triggers flares?

Hang-Korng EA (France)

MORNING - SESSION 2

Chairs: Hang-Korng EA (France), Frédéric LIOTE (France)

10.50

Environmental factors and hyperuricemia

Thomas BARDIN (France)

11.15

Renal handling of urate: role of environmental factors

Emmanuel LETAVERNIER (France)

Oral communications - Session 3

Chairs: Tania CRISAN (Romania), Sonia NASI (Switzerland / Netherlands)

11.40

Biomarker found in plasma has potential to differentiate between gout and CPPD disease

Brenda KISCHKEL (Netherlands)

11.50

Identification of metabolite profiles during gout flare in a prospective gout cohort: glutamine and histidine as anti-inflammatory metabolites

Charles LEROY (France)

12.00

A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition.

Mariano ANDRÉS (Spain)

AFTERNOON - SESSION 1

Chairs: Frédéric LIOTÉ (France), Hang-Korng EA (France)

13.30

Can we stop urate lowering therapy in people with gout?

Pascal RICHETTE (France)

13.55

How low is too low? Tailored goutology (video recorded)

Fernando PEREZ-RUIZ (Spain)

AFTERNOON - SESSION 2

Chairs: Frédéric LIOTÉ (France), Alexander SO (Switzerland)

Oral communications - Session 4

14.30

Exploring Quality of Life Outcomes in Gout in Patients on a Treat-to-Target (TTT) Regime

Rowan HART (United Kingdom)

14.40

IL1β promoter polymorphism rs16944 and cytokine production in hyperuricemia and gout

Maria MUNTIU (Romania)

14.50

The Young, the Metabolic and the Hypertensive. A cluster analysis of gout patients and its comorbidities

Cesar DIAZ-TORNE (Spain)

15.00

Cost-effectiveness of nurse-led home monitoring of serum uric acid values for gout patients in secondary care: a modelling study

Marcel FLENDRIE (Netherlands)

15.10

Safety and efficacy of monthly dosing of pegloticase (every 4 weeks) with methotrexate co-administration in patients with uncontrolled gout: phase 4 forward open-label trial

Brian LAMOREAUX (United States)

15.20

Defining colchicine in-vitro effect on MSU crystals stimulated peripheral blood mononuclear cells

Laura MERLO PICH (Netherlands)

15.30

Intra-articular sustained-release treatment with microspheres containing colchicine is effective in an inflammatory arthritis rat model

Marie-Christophe BOISSIER (France)

15.40

Allopurinol associated cardiovascular risk and protective effect of colchicine in gout patients: a Dutch nationwide pharmaco-epidemiologic cohort study

Noortje VAN HERWAARDEN (Netherlands)

15.50

Low dose colchicine (or not) in preventing CV events (Live video)

Michael PILLINGER (United States)

16.30

FAREWELL

Frédéric LIOTÉ (France), Hang-Korng EA (France)